OCT4 Positively Regulates Survivin Expression to Promote Cancer Cell Proliferation and Leads to Poor Prognosis in Esophageal Squamous Cell Carcinoma

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Li, Chunguang ^a,b   Yan, Yan ^a   Ji, Weidan ^a   Bao, Longlong ^a   Qian, Haihua ^a   Chen, Lei ^a   Wu, Mengchao ^a   Chen, Hezhong ^b   Li, Zhigang ^b   Su, Changqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; SHORT HAIRPIN RNA; SURVIVIN;

ADULT; AGED; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC CORRELATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; SURVIVAL TIME; UPREGULATION;

AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84869807785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049693     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, et al. (2001) Skeletonizing en bloc esophagectomy for cancer. Ann Surg 234: 25-32.
3. Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, et al. (2011) Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 6: e21419.
4. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, et al. (2006) Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251.
5. Wang Q, He W, Lu C, Wang Z, Wang J, et al. (2009) Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 29: 1233-1241.
6. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, et al. (2007) Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 25: 500-510.
7. Pan GJ, Chang ZY, Scholer HR, Pei D, (2002) Stem cell pluripotency and transcription factor Oct4. Cell Res 12: 321-329.
8. Ezeh UI, Turek PJ, Reijo RA, Clark AT, (2005) Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265.
9. Gu G, Yuan J, Wills M, Kasper S, (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67: 4807-4815.
10. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, et al. (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: e2637.
11. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR, (2007) OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120: 1598-1602.
12. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085-4095.
13. Chen Z, Xu WR, Qian H, Zhu W, Bu XF, et al. (2009) Oct4, a novel marker for human gastric cancer. J Surg Oncol 99: 414-419.
14. Zhou X, Huang GR, Hu P, (2011) Over-expression of Oct4 in human esophageal squamous cell carcinoma. Mol Cells 32: 39-45.
15. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM, (2007) Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60.
16. Andersen MH, Svane IM, Becker JC, Straten PT, (2007) The universal character of the tumor-associated antigen survivin. Clin Cancer Res 13: 5991-5994.
17. Mega S, Miyamoto M, Li L, Kadoya M, Takahashi R, et al. (2006) Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma. Dis Esophagus 19: 355-359.
18. Cao M, Yie SM, Wu SM, Chen S, Lou B, et al. (2009) Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 26: 751-758.
19. Hoffmann AC, Vallbohmer D, Grimminger P, Metzger R, Prenzel KL, et al. (2010) Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 11: 341-347.
20. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, et al. (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92-95.
21. Trabulo S, Cardoso AM, Santos-Ferreira T, Cardoso AL, Simoes S, et al. (2011) Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm 8: 1120-1131.
22. Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, et al. (2012) Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol Cancer Ther 11: 204-213.
23. Prud'homme GJ (2012) Cancer Stem Cells and Novel Targets for Antitumor Strategies. Curr Pharm Des.
24. Kim RJ, Nam JS, (2011) OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Lab Anim Res 27: 147-152.
25. Guo Y, Mantel C, Hromas RA, Broxmeyer HE, (2008) Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin. Stem Cells 26: 30-34.
26. Gil J, Stembalska A, Pesz KA, Sasiadek MM, (2008) Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet 49: 193-199.
27. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, et al. (2009) Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 18: 1093-1108.
28. Cheng L, Sung MT, Cossu-Rocca P, Jones TD, MacLennan GT, et al. (2007) OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol 211: 1-9.
29. Yuan F, Zhou W, Zou C, Zhang Z, Hu H, et al. (2010) Expression of Oct4 in HCC and modulation to wnt/beta-catenin and TGF-beta signal pathways. Mol Cell Biochem 343: 155-162.
30. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
31. Margulis V, Lotan Y, Shariat SF, (2008) Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 26: 59-65.
32. Guha M, Altieri DC, (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8: 2708-2710.
33. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, et al. (2010) Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 16: 6150-6158.
34. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, et al. (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27: 4481-4486.
35. Zhonghong L, Lianjie L, Changqing Z, Ying H, Yu J, et al. (2008) The influence of survivin shRNA on the cell cycle and the invasion of SW480 cells of colorectal carcinoma. J Exp Clin Cancer Res 27: 20.
36. Liu JL, Wang Y, Jiang J, Kong R, Yang YM, et al. (2010) Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA. Chin Med J (Engl) 123: 2901-2907.
37. Pennati M, Binda M, Colella G, Zoppe M, Folini M, et al. (2004) Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23: 386-394.
38. Pietenpol JA, Stewart ZA, (2002) Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 181-182: 475-481.
39. Zhao X, Guo J, Yu Y, Yi S, Yu T, et al. (2011) Overexpression of survivin and cyclin D1 in CHO cells confers apoptosis resistance and enhances growth in serum-free suspension culture. Biotechnol Lett 33: 1293-1300.
40. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104: 7391-7396.
41. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, et al. (2005) Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115: 967-974.
42. Cosgrave N, Hill AD, Young LS, (2006) Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol 37: 377-390.
43. Friedrichs K, Gluba S, Eidtmann H, Jonat W, (1993) Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647.